GlassScriptPhysician profile
Anthony C Theodoris
NPI 1578675971
$11,849.94
in general payments reported to CMS, 2019-2025
39 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,914 · 2020: $1,409 · 2021: $1,779 · 2022: $1,873 · 2023: $1,556 · 2024: $1,681 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,874.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,319.52 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,088.44 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,229.80 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $585.57 | 2019-2024 | Yupelri |
| Genzyme Corporation | $525.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $443.43 | 2019-2025 | Dupixent |
| Amgen INC. | $390.95 | 2022-2025 | Tezspire |
| Electromed, INC. | $310.33 | 2019-2024 | Smartvest |
| Ani Pharmaceuticals, INC. | $301.48 | 2022-2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $267.38 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $222.42 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $198.39 | 2019-2020 | |
| Advanced Respiratory, INC | $151.30 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $147.29 | 2019-2021 | |
| Viatris Specialty LLC | $140.05 | 2025 | Yupelri |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $139.21 | 2019-2024 | Recarbrio, Dificid, Zerbaxa |
| Grifols USA, LLC | $128.99 | 2019-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $125.88 | 2020-2025 | |
| Pfizer INC. | $125.41 | 2019-2023 | |
| Philips North America LLC | $121.03 | 2020-2025 | Vest Therapy Und |
| Insmed, INC. | $114.09 | 2023-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $78.60 | 2022-2023 | Aralast, Cuvitru |
| Verona Pharma, INC. | $78.40 | 2025 | Ohtuvayre |
| Zoll Respicardia, INC. | $76.84 | 2024 | Remede System |
| Jazz Pharmaceuticals INC. | $73.36 | 2021-2023 | |
| Mallinckrodt Enterprises LLC | $69.26 | 2019 | |
| Allergan, INC. | $65.86 | 2019-2020 | |
| Baxter Healthcare | $49.83 | 2022 | |
| Circassia INC. | $46.21 | 2019-2020 | |
| Vifor Pharma, INC. | $40.47 | 2024 | Zemaira |
| Teva Pharmaceuticals USA, INC. | $37.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $32.86 | 2019 | |
| Inspire Medical Systems, INC. | $25.33 | 2023 | Inspire |
| Chiesi USA, INC. | $23.98 | 2019 | |
| Nabriva Therapeutics, Plc | $18.83 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.12 | 2020 | |
| Olympus America INC. | $15.08 | 2020 | |
| Abbvie INC. | $13.23 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Theodoris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.